anterior uveitis and ocular hypotony in cidofovir-treated patients with AIDS-related CMV retinitis in two London ophthalmology departments.
Methods
A retrospective review was performed of all patients with AIDS-related CMV retinitis attending two ophthalmology departments during the 12-month period September 1996 to August 1997. In each case the CMV retinitis activity, concurrent illnesses and medications, and CD4 + lymphocyte count were recorded in addition to the degree of anterior chamber inflammation (cells, flare, keratic precipitates and posterior synechiae) and intraocular pressure at each visit during the study period.
Treatment with intravenous cidofovir was given according to a standardised protocol including pretreatment and concomitant oral probenecid and intravenous hydration. Ocular hypotony was defined as an intraocular pressure of 5 mmHg or less. The frequency of uveitis and ocular hypotony in cidofovir-treated patients was determined and the possible influence of other ocular and systemic factors considered. Statistical analysis was performed using a chi-squared test with Yates' correction for small numbers.
Results
A total of 26 patients (25 men and 1 woman; mean age 38.4 years, range 31-58 years) with CMV retinitis attended during the study period. Nine patients received intravenous cidofovir. Eight (89%) of the 9 patients who received intravenous cidofovir subsequently developed anterior uveitis.
The numbers of patients with potential risk factors for anterior uveitis are shown in Table 1 . Anterior uveitis was significantly associated with concurrent use of intravenous cidofovir but not with concurrent use of rifabutin or HAART. Nor was there a significant association with higher CD4 + lymphocyte counts defined as any increase above the patient's prior lowest level or as stratified according to an absolute level greater than 50, 100 or 150 cells/f.d.
Seven patients presented between 4 and 10 weeks after induction with cidofovir (three to six infusions) and one presented after 8 months of treatment. Table 2 shows the features of anterior uveitis in cidofovir-treated patients. The uveitis was bilateral in 7 of the 8 patients. 
Six of the 8 cidofovir-treated patients with anterior uveitis had bilateral CMV disease. One patient with unilateral (inactive) CMV disease developed bilateral uveitis following cidofovir treatment. In only 1 patient was the CMV retinitis clinically active at the onset of uveitis. In 4 patients there was an early rapid formation of extensive posterior synechiae with subsequent iris transillumination defects. All patients with anterior uveitis were treated at presentation with topical corticosteroids and mydriatics. The cellular anterior chamber activity resolved with topical steroid administration in all eyes with uveitis but tended to recur on withdrawal of steroids. Significant flare persisted despite topical steroids in 3 patients. The posterior synechiae responded poorly to topical mydriatic therapy, resulting in inadequate mydriasis which significantly limited the fundal view. In 1 of the 9 cidofovir-treated patients there was a progressive reduction in intraocular pressure to less than 5 mmHg, resulting in unilateral hypotonous maculopathy with reduction of acuity to 6/18. Following cessation of cidofovir therapy in this patient the intraocular pressure initially increased with an improvement in the maculopathy, but subsequently fluctuated between 4 mmHg and 8 mmHg. The association of cidofovir with hypotony in this small series was not statistically significant.
Intravenous cidofovir treatment was discontinued in one additional patient, primarily as a result of renal toxicity. Although this patient had persistent posterior synechiae there was no evidence of active anterior uveitis 4 weeks later.
Discussion
Anterior uveitis occurred in 8 of 9 (89%) cidofovir-treated patients compared with 26% previously reported. I S Although this small descriptive study offers little evidence of causality the association is strong and there was a clear temporal relationship in the majority of cases. Evidence supporting the role of cidofovir in uveitis includes the dose-dependence of uveitis following intravitreal injection 13 and the protection against uveitis with the use of probenecid. I 2 Probenecid reduces the risk of renal toxicity due to cidofovir by reducing its peak concentration in the proximal tubule, and may have a similar protective effect on the ciliary body.
In this series cidofovir was the only significant risk factor identified but the aetiology of anterior uveitis in this group of patients may be multifactorial. Although we did not find an association with the use of rifabutin or HAART, or with higher CD4 + lymphocyte counts, the study is small and does not exclude factors that may have been identified had the number of patients been greater. Rifabutin is well known to cause uveitis, 17 especially with concomitant clarithromycin or fluconazole. 18 The risk of uveitis in cidofovir-treated patients has been associated with HAART; lS increased immunocompetence may predispose to uveitis by enhancing inflammatory responses. Anterior uveitis is an atypical feature of active CMV retinitis itself, 19 but in only 1 of 8 cidofovir-treated patients in this study was the CMV retinitis active at the onset of the uveitis.
The uveitis developed after three to six infusions of cidofovir in 7 of the 8 patients. The uveitis mainly affected eyes with previous CMV disease, although one patient with unilateral inactive CMV disease developed bilateral uveitis. The breakdown of the blood-retinal barrier induced by CMV retinitis may increase the concentration of the systemic drug and make eyes with previous disease more likely to develop toxic reactions than eyes with intact barriers. The uveitis was typically bilateral, moderately severe, non-granulomatous and characterised in 4 cases by the early and rapid formation of extensive posterior synechiae. Treatment with topical corticosteroids controlled the cellular anterior chamber activity in all cases and continued steroid treatment was required to prevent recurrences while cidofovir therapy was continued. After the onset of the uveitis, any effect of sequential infusions of cidofovir on its intensity was masked by this treatment, but there was no suggestion of a tendency for the uveitis to become less aggressive with time. Despite initiation of topical mydriatic therapy at presentation, established posterior synechiae responded poorly and inadequate mydriasis resulted in a Significantly limited fundal view. This presented considerable problems in monitoring the activity and progression of CMV retinitis.
Intravitreal injection of cidofovir can cause irreversible visually significant hypotony lO and is associated with ciliary body atrophy on ultrasound biomicroscopy. ll This effect may be analogous to the secretory toxicity of cidofovir in the proximal tubule of kidney. The guinea pig eye shows a similar reduction in intraocular pressure after intravitreal cidofovir and the ciliary body changes are dose-dependent. 20 The patient in this series with hypotonous maculopathy responded to withdrawal of intravenous cidofovir therapy by an increase in intraocular pressure and improvement of the maculopathy, although the intraocular pressure subsequently fluctuated between 4 mmHg and 8 mmHg. Although one study found no change in intraocular pressure with intravenous cidofovir, 21 others have reported a 50% reduction in intraocular pressure in up to 5% of patients treated. IS Intraocular pressures in patients with HIV infection are lower than normal, however, correlating with both CD4 + lymphocyte count and the extent of CMV retinitis. 22 This difference is of importance, not only because the reference range in these patients is lower but also because any further reduction in intraocular pressure carries a greater risk of hypotony and visually significant maculopathy. 
